Bicycle Therapeutics plc Increase (Decrease) in Other Noncurrent Liabilities
Bicycle Therapeutics plc (BCYC) reported Increase (Decrease) in Other Noncurrent Liabilities of $189.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-03-17
- Bicycle Therapeutics plc increase (decrease) in other noncurrent liabilities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Bicycle Therapeutics plc increase (decrease) in other noncurrent liabilities for the quarter ending 2024-09-30 was $52.00K, a 60.31% decline year-over-year.
- Bicycle Therapeutics plc increase (decrease) in other noncurrent liabilities for the quarter ending 2024-06-30 was $78.00K, a 48.34% decline year-over-year.
- Bicycle Therapeutics plc increase (decrease) in other noncurrent liabilities for the quarter ending 2024-03-31 was $59.00K, a 63.13% decline year-over-year.
- Bicycle Therapeutics plc increase (decrease) in other noncurrent liabilities for fiscal 2024 was $189.00K, a 62.87% decline from fiscal 2023.
- Bicycle Therapeutics plc increase (decrease) in other noncurrent liabilities for fiscal 2023 was $509.00K, a 23.80% decline from fiscal 2022.
- Bicycle Therapeutics plc increase (decrease) in other noncurrent liabilities for fiscal 2022 was $668.00K, a 5.92% decline from fiscal 2021.
- Bicycle Therapeutics plc increase (decrease) in other noncurrent liabilities for fiscal 2021 was $710.00K, a 37.33% increase from fiscal 2020.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $52.00K derived: sum of 2 quarters · filed 2026-03-17 | $130.00K derived: sum of 3 quarters · filed 2026-03-17 | $189.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $130.00K derived: sum of 2 quarters · filed 2025-10-30 | $189.00K 10-Q · filed 2025-10-30 | $256.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $137.00K 10-Q · filed 2025-08-08 | $204.00K derived: sum of 3 quarters · filed 2026-03-17 | $335.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $59.00K 10-Q · filed 2025-05-01 | $126.00K derived: sum of 2 quarters · filed 2026-03-17 | $257.00K derived: sum of 3 quarters · filed 2026-03-17 | $408.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $198.00K derived: sum of 2 quarters · filed 2026-03-17 | $349.00K derived: sum of 3 quarters · filed 2026-03-17 | $509.00K 10-K · filed 2026-03-17 |
| 2023-09-30 | $131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $282.00K derived: sum of 2 quarters · filed 2024-10-31 | $442.00K 10-Q · filed 2024-10-31 | $607.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $311.00K 10-Q · filed 2024-08-06 | $476.00K derived: sum of 3 quarters · filed 2025-02-25 | $645.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $160.00K 10-Q · filed 2024-05-02 | $325.00K derived: sum of 2 quarters · filed 2025-02-25 | $494.00K derived: sum of 3 quarters · filed 2025-02-25 | $650.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $334.00K derived: sum of 2 quarters · filed 2025-02-25 | $490.00K derived: sum of 3 quarters · filed 2025-02-25 | $668.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $325.00K derived: sum of 2 quarters · filed 2023-11-02 | $503.00K 10-Q · filed 2023-11-02 | $732.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $334.00K 10-Q · filed 2023-08-03 | $563.00K derived: sum of 3 quarters · filed 2024-02-20 | $727.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $178.00K 10-Q · filed 2023-05-04 | $407.00K derived: sum of 2 quarters · filed 2024-02-20 | $571.00K derived: sum of 3 quarters · filed 2024-02-20 | $717.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $393.00K derived: sum of 2 quarters · filed 2024-02-20 | $539.00K derived: sum of 3 quarters · filed 2024-02-20 | $710.00K 10-K · filed 2024-02-20 |
| 2021-09-30 | $164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $310.00K derived: sum of 2 quarters · filed 2022-11-03 | $481.00K 10-Q · filed 2022-11-03 | $629.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $317.00K 10-Q · filed 2022-08-04 | $465.00K derived: sum of 3 quarters · filed 2023-02-28 | $601.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $171.00K 10-Q · filed 2022-05-05 | $319.00K derived: sum of 2 quarters · filed 2023-02-28 | $455.00K derived: sum of 3 quarters · filed 2023-02-28 | $536.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $284.00K derived: sum of 2 quarters · filed 2023-02-28 | $365.00K derived: sum of 3 quarters · filed 2023-02-28 | $517.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $136.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $217.00K derived: sum of 2 quarters · filed 2021-11-04 | $369.00K 10-Q · filed 2021-11-04 | $819.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $233.00K 10-Q · filed 2021-08-05 | $683.00K derived: sum of 3 quarters · filed 2022-03-01 | $893.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $152.00K 10-Q · filed 2021-05-06 | $602.00K derived: sum of 2 quarters · filed 2022-03-01 | $812.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.05M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $660.00K derived: sum of 2 quarters · filed 2022-03-01 | $898.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.09M 10-K · filed 2022-03-01 |
| 2019-09-30 | $210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $448.00K derived: sum of 2 quarters · filed 2020-11-05 | $639.00K 10-Q · filed 2020-11-05 | $774.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $429.00K 10-Q · filed 2020-08-05 | $564.00K derived: sum of 3 quarters · filed 2021-03-11 | $709.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $191.00K 10-Q · filed 2020-05-07 | $326.00K derived: sum of 2 quarters · filed 2021-03-11 | $471.00K derived: sum of 3 quarters · filed 2021-03-11 | |
| 2018-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $280.00K derived: sum of 2 quarters · filed 2021-03-11 | $543.00K 10-K · filed 2021-03-11 | |
| 2018-09-30 | $145.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $408.00K 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $263.00K 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $383.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |